

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/150495> since

Published version:

DOI:10.1158/2159-8290.CD-14-0001

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[Cancer Discovery, volume 4, issue 9, 2014, doi: 10.1158/2159-8290.CD-14-0001]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[<http://cancerdiscovery.aacrjournals.org/content/4/9/998.long>]

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Manuel Hidalgo^{1,*}, Frederic Amant⁴, Andrew V. Biankin⁵, Eva Budinská⁸, Annette T. Byrne⁹, Carlos Caldas⁶, Robert B. Clarke⁷, Steven de Jong¹⁰, Jos Jonkers¹¹, Gunhild Mari Mælandsmo¹², Sergio Roman-Roman¹³, Joan Seoane², Livio Trusolino^{14,15}, Alberto Villanueva³, for the EurOPDX Consortium

Author Affiliations

¹Centro Nacional de Investigaciones Oncológicas, Madrid;

²Vall d'Hebron Institute of Oncology;

³Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain;

⁴Katholieke Universiteit Leuven, Leuven, Belgium;

⁵Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow;

⁶Cambridge Cancer Centre, Cambridge;

⁷Breakthrough Breast Cancer Unit, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom;

⁸Masaryk University, Brno, Czech Republic;

⁹Royal College of Surgeons in Ireland, Dublin, Ireland;

¹⁰Department of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen;

¹¹The Netherlands Cancer Institute, Amsterdam, the Netherlands;

¹²Oslo University Hospital, Oslo, Norway;

¹³Institut Curie, Paris, France;

¹⁴Candiolo Cancer Institute – FPO IRCCS; and

¹⁵Department of Oncology, University of Torino, Candiolo, Torino, Italy

*Corresponding Author:

Manuel Hidalgo, Centro Nacional de Investigaciones Oncológicas, Melchor Fernandez Almagro 3, 28029, Madrid, Spain. Phone: 34-91-732-8000; Fax: 34-91-224-6980; E-mail: mhidalgo@cni.es

Abstract

Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.

Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field.

Introduction

The use of preclinical models is a core component in every aspect of translational cancer research, ranging from the biologic understanding of the disease to the development of new treatments (1, 2). With regard to drug development, the use of human cancer models for drug screening began at the NCI in the 1970s following a nearly three-decade period in which screening of new drugs was performed in rapidly growing murine models. Over the past 40 years, a number of studies have established basic methodology and a systematic approach for preclinical testing of anticancer agents both *in vitro* and *in vivo* (1, 2). Currently, the NCI-60 cancer cell line panel represents the best-characterized and most frequently used collection of human cancer models used for *in vitro* drug screening and development (3). These cells

were derived from patients with cancer and have been adapted to grow indefinitely in artificial culture conditions. Xenografts developed by growing these cell lines subcutaneously in immunodeficient mice are the most commonly used *in vivo* platform in preclinical drug development.

These so-called conventional cell lines, although convenient and easy to use, have important limitations in preclinical drug development. The most relevant is their lack of predictive value with regard to activity in specific cancer types in clinical trials. Although, in general, agents active in at least one third of the preclinical models explored to date showed activity in phase II clinical trials, there has been poor prediction for activity in specific disease entities, except in lung cancer (4). Although the underlying cause of this limited predictive value is not fully understood, evidence suggests that the process of generating cancer cell lines results in major and irreversible alterations in biologic properties, including gain and loss of genetic information, alteration in growth and invasion properties, and loss of specific cell populations (5, 6). In addition, cell lines are usually established only from the more aggressive tumors and hence are not representative of complex tumor heterogeneity evident in the clinic. For all these reasons, the establishment of cell lines is not an appropriate strategy for personalized medicine applications. Novel approaches, such as short-term primary cultures or organoids, are being developed, although important validation studies are still required before broad application in conventional preclinical screening projects.

In an attempt to circumvent these issues, there has been increasing interest in the application of more advanced preclinical cancer models, including patient-derived tumor xenograft (PDX) as well as genetically engineered mouse models (GEMM). PDX models are not new, and studies conducted in the 1980s have already shown a high degree of correlation between clinical response to cytotoxic agents in adult patients with lung cancer and response to the same agent in PDX models generated from these patients (7). Similar observations were made in studies of childhood rhabdomyosarcomas (8). In addition, PDX models have been used to conduct preclinical phase II studies with classic chemotherapeutics (9). In recent years, there has been a renewed interest in the development of PDX models from different tumor types. Indeed, these models are becoming the preferred preclinical tool in both the industry and academic groups in an attempt to improve the drug development process (10–12). Currently, there are several collections of extensively characterized PDX models in use for different translational research applications. These collections broadly represent the complex clinical tumor heterogeneity and molecular diversity of human cancers. In this article, we review current methodology for the generation of PDX models, provide a summary of currently available collections of these models, list current applications and major contributions of PDX models to cancer therapeutics and personalized medicine, and highlight important issues for the future development of this approach. Finally, we introduce a European initiative aimed at establishing an academic consortium of laboratories having established collections of PDX models with the goal of triggering scientific collaboration, conducting multicenter preclinical trials, and developing new models. As studies demonstrate the significant heterogeneity of human cancer, large collections of PDX models, not affordable by individual groups but through the setup of collaborative networks, are key to tackling the challenge of precision medicine.

Methodologic Aspects

The process of generating PDX models in mice from fresh primary or metastatic human cancer is extensively described in the literature (10, 13). Although individual groups have developed specific methodologic approaches, the fundamentals are common. Table 1 provides a summary of approaches used to generate the most comprehensive PDX collections currently available. Briefly, pieces of primary or metastatic solid tumors maintained as tissue structures are collected by surgery or biopsy procedures. Some studies have also used fluid drained from malignant ascites or pleural effusions. Tumors are implanted as pieces or single-cell suspensions, either alone or in some studies coated with Matrigel or mixed with human fibroblasts or mesenchymal stem cells. The most common site of implantation is on the dorsal region of mice (*subcutaneous implantation*), although implantation in the same organ as the original tumor may be an option (*orthotopic implantation*, i.e., pancreas, oral cavity, ovary, mammary fat pad, brain, etc.). In addition, independent of the tumor origin, several approaches have implanted primary tumors in the renal capsule in an effort to

increase engraftment success rates. A variety of mouse strains having different degrees of immunosuppression have been used in these studies. Supplementary Table S1 lists the principal characteristics of the most commonly used mouse strains, including their level of immune suppression as well as advantages or disadvantages. For hormone-sensitive tumors, some studies have used hormone supplementation with the intent of increasing engraftment rates.

Some approaches may have theoretical advantages with regard to higher and faster engraftment rates and generation of models that better recapitulate human tumors and are, therefore, more predictive. However, it is important to mention that very few studies have properly addressed comparative implantation methods for these endpoints. Studies in which PDX models have been generated simultaneously from primary tumors and metastatic lesions suggest that metastases have a higher engraftment rate (14, 15). Defining the most appropriate host mouse strains to generate PDX models is an important consideration. It is assumed that more severely immunosuppressed models, such as NOD/SCID or NOD/SCID/IL2 λ -receptor null (NSG) models, are better suited for PDX generation due to higher engraftment rates. Indeed, these are the preferred rodent strains for many groups. However, in human breast cancer, where this question has been robustly interrogated, implantation in NOD/SCID versus NSG mice yielded similar take rates (16). In addition, host supplementation with estradiol pellets increased engraftment rates from 2.6% to 21.4%, whereas, for reasons that are unclear, coimplantation with immortalized human fibroblasts decreased engraftment rate (16). In contrast, in another study, a mixture of irradiated and nonirradiated human fibroblasts provided improved results (17). Likewise, orthotopic tumor implantation ("orthoxenografts"; ref. 18) may also confer a translational advantage, as the tumor develops in the same anatomic microenvironment. The generation of orthoxenografts is more labor-intensive, requires complex surgery, is more expensive, and often requires imaging methods to monitor tumor growth. However, for several tumor types (e.g., ovarian cancer or lung cancer), this approach substantially increases tumor take rates (19). In this vein, orthotopic implantation in the testis is essential for the growth of testicular germ cell tumors. As for tumor implantation in the renal capsule, it yielded an impressive 90% engraftment rate in non-small cell lung cancer (NSCLC) as compared with 25% following subcutaneous implantation, although these results were not obtained from a single comparative study (20, 21). Furthermore, renal cell capsule implantation shortens time to engraftment, which is one of the most important variables for studies seeking to implement real-time PDX data for personalized cancer treatment (20).

Salient Features of PDX Models

As mentioned, the principal limitation of conventional preclinical models ("*in vitro*" cell line studies as well as "*in vivo*" xenograft models generated by implanting these cells in immunodeficient mice) is their poor predictive value with regard to clinical outcome (4). The reasons why conventional cancer models have such poor predictive power are not completely understood. However, variations in the basic biology of the models as they evolve are likely a key factor. The process of adaptation to *in vitro* growth conditions leads to changes in the biologic circuits of the cancer cells that differ from the host-derived entity. These include modifications in key properties such as genetic content, invasive capabilities, maintenance of a heterogeneous cell population, and the reliance on specific growth and survival pathways (6).

The rationale for developing PDX models is based on the expectation that these models will represent enhanced preclinical tools and will be more predictive of human cancer biology and patient response to treatments. In addition, PDX models offer the potential for personalizing patient cancer treatment. Proving the value of PDX models may be approached from different perspectives: one such approach is to compare the histopathologic, biologic, and genetic features of a PDX model with its donor tumor (also called "validation"). The underlying hypothesis is that PDX models will retain key characteristics of the donor tumor and that these characteristics will be maintained through successive mouse-to-mouse passages *in vivo*. Table 2 summarizes the data from different studies in which PDX models have been compared with donor tumors using a variety of methods. In general, these studies show that PDX models retain the principal characteristics of donor tumors, including fine tissue structure and subtle microscopic details such as gland architecture, mucin production, or cyst development. At the biologic level, most studies also show good concordance between tumors and the models derived from them. An analysis of gene expression profiles shows that there are no substantial changes between donor tumors and their corresponding PDX, with only genes involved in the stromal compartment and immune function being less represented in models, due to the replacement of the human stroma by murine elements. Indeed, using unsupervised clustering analysis, paired donor tumor and PDX models cluster together

in most of the studies. Analyses of copy-number alterations (CNA) and exome sequencing data also show extraordinary concordance between paired samples, with a trend toward higher frequency of genomic alterations in the PDX model likely as a result of increased human tumor DNA purity in the PDX model. Indeed, in PDX, the cross-contamination by normal DNA from the human stromal tissue is avoided. A recent study reports whole-genome sequencing of several trios (primary tumors, lymphocytes, and PDX) in breast cancer, showing that PDX have relatively stable genomes without a significant accumulation of DNA structural rearrangements but with some enrichment for PDX-unique single-nucleotide variants (22). These PDX-unique mutations could be the result of adaptation to transplantation into the new microenvironment, but could also be present in the original tumor below detectable limits. A study showed that many CNA changes found in sarcoma PDX are frequently observed in patients with sarcoma, suggesting that xenografts may in some way represent the genomic rearrangement intrinsic to tumor progression (23). This was also suggested in another study describing that many of the mutations detected in the breast PDX were also observed in brain metastases derived from the same patient (24). Furthermore, mouse-to-mouse propagation does not substantially change the functional characteristics of the grafted tumor. Studies that have compared the response to drug treatments of PDX models from different passages (up to 10) show stable response rates across generations, further supporting the phenotypic stability of these models (25, 26). In contrast, an interesting study compared the gene expression profiles of a donor tumor with those of PDX models and cell lines developed from that tumor, both *in vitro* and *in vivo* in conventional xenograft models. The data show that although the gene expression profile of PDX models is similar to the original tumor, cell lines developed from the same specimen display a different expression profile that is not restored by *in vivo* subcutaneous propagation in mice (27).

An additional way to examine model fidelity as compared with the original tumor is to focus on well-known disease-based genomic alterations rather than directly comparing an individual donor with PDX characteristics. In PDX models of squamous cell carcinoma of the head and neck (SCCHN), for example, the prevalence of *TP53* and *NOTCH* mutations is similar to those reported in human tumors (25). Similar results have been observed in colorectal cancer and pancreatic ductal adenocarcinoma (PDAC) models in which the frequency of mutations in genes such as *TP53* or *RAS* closely mirrors the frequency of these mutations in human samples (26, 28, 29). In human breast cancer PDX models, several studies using gene expression profiles have shown that intrinsic breast cancer phenotypes are well represented and in concordance with the original tumors (16, 30, 31). Nevertheless, estrogen receptor-positive (ER⁺) subtypes are underrepresented, in particular, the recently described ER⁺ subtypes with good prognosis. Furthermore, when examining metabolism, the metabolic profiles as detected by high-resolution magic angle spinning magnetic resonance (MR) spectroscopy are remarkably similar when comparing patient material and tissue from orthotopically growing basal-like and luminal-like breast cancer (32).

A complementary approach to determine the value of PDX models in cancer research (discussed and illustrated below) is by analyzing the predictive value of the data obtained from PDX studies with regard to drug efficacy, biomarker analysis, and patient outcome. In this sense, a similar level of activity as observed in the clinic has consistently been shown in studies in which clinically applied drugs or regimens have been tested in PDX models. Table 3 provides a summary of studies in which PDX models from different cancer types have been treated with agents used in the clinical care of these patients. Although the analysis of data is complicated by different response criteria used, in general, there is a remarkable similarity between the activity of agents, such as cetuximab in colorectal cancer models and gemcitabine in PDAC models, and respective clinical trial data (28, 29, 33). Of even greater relevance is the remarkable one-to-one concordance in studies that compare the individual donor patient response to conventional anticancer agents with that of his or her PDX (16, 21, 33, 34). Furthermore, the analysis of clinically validated biomarkers, such as *KRAS* mutations, and resistance to EGFR inhibitors in PDX studies reached the same conclusions as clinical trials, as discussed in more detail below (28). Finally, emerging studies in which patients have been treated with drugs selected for their activity against their PDX counterparts show a high predictive power, further supporting the notion that response in PDX models correlates with clinical outcome (35).

Applications of PDX Models in Cancer Research

Drug Screening and Biomarker Development

It is well known that one of the major issues in oncology drug development is the low success rate of new agents (36). Many compounds are advanced to large phase III studies, which consume considerable resources, to end up failing because of a lack of efficacy. Part of the reason for these poor results is that conventional preclinical models used to screen new agents for clinical development have poor predictive value (4). In addition, new drugs are, in general, tested without appropriate biomarkers for patient selection and response monitoring. Thus, strategies to diminish this high attrition rate are needed. In this regard, the availability of preclinical models with high predictive value is of major interest, as it will permit the conducting of preclinical phase II studies to select potential indications for subsequent clinical trials.

The rationale for implementing PDX models to achieve this objective relies on the fact that these models are predictive of clinical outcome. This has been shown in several retrospective studies and more recently in prospective clinical trials. As listed in Table 3, a number of reports in colorectal cancer, NSCLC, SCCHN, human breast cancer, and renal cell cancer (RCC) have tested the response rate of drugs used as standard of care in medical oncology in PDX models. These experiments show that the response rates in PDX models correlate with those observed in the clinic, both for targeted agents and for classic cytotoxics. For example, an extensive analysis of the EGFR inhibitor cetuximab in 47 unselected colorectal cancer PDX models showed a 10.6% response rate, which is identical to the response rate observed with this agent in patients with this disease (28). Similar data have also been published for SCCHN, the other indication in which cetuximab is commonly used (25). The MEK and PI3K/mTOR inhibitors proved to be poorly effective in a panel of 40 *KRAS*-mutant colorectal cancer PDX models, again in accordance with clinical data from phase I trials (37). In RCC, PDX models showed response to the mTOR inhibitor sirolimus and the angiogenesis inhibitors sunitinib and dovitinib, but not to erlotinib as was also observed in clinical trials (15). With regard to conventional chemotherapy, studies in NSCLC, human breast cancer, colorectal cancer, and PDAC demonstrated that response rates to clinically used agents, such as paclitaxel, carboplatin, gemcitabine, 5-fluorouracil, irinotecan, and adriamycin, among others, are comparable between PDX models and clinical data (Table 3).

More recently, the role of PDX models as potential screening platforms for clinical trials has also been shown in a prospective study in PDAC. This work showed that the combination of *nab*-paclitaxel and gemcitabine is effective in PDX models of PDAC, a finding that correlated with the clinical efficacy of this combination. In fact, this regimen has recently been demonstrated to provide a survival benefit for patients with advanced PDAC in a randomized phase III study, and is likely to become a standard of care in this setting (38). Likewise, failure to exert antitumor efficacy in PDX models correlates with negative clinical results. This is illustrated in PDAC for agents such as the SRC inhibitor saracatinib and the mTOR inhibitor sirolimus, for which lack of efficacy in unselected PDX preclinical studies predicted failure of the same strategy in the clinic (39, 40). Based on these data, PDX models have now become an integral part of the preclinical screening of new anticancer agents.

One critical aspect of large preclinical studies in PDX models is that they not only help to prioritize potential clinical indications, but may also facilitate the identification of potential drug efficacy biomarkers. The concordance between PDX models and human trials with regard to biomarkers of drug susceptibility and drug resistance is indeed notable. In colorectal cancer, for example, it has been clearly shown in a number of studies that *KRAS*-mutant PDX models do not respond to cetuximab. *KRAS* wild-type status is now a well-documented clinical biomarker for this targeted therapy (28, 29). Similar data were observed in NSCLC (21). In fact, it could be argued that if these preclinical studies had been conducted before or in parallel to the clinical development of cetuximab, the discovery, validation, and approval of *KRAS* mutation as a marker of resistance would have been expedited. In PDAC, PDX studies with gemcitabine identified expression of the gemcitabine-activating enzyme deoxycytidine kinase as a predictor of drug efficacy. A subsequent analysis of this marker in clinical samples confirmed these results (26, 41). Likewise, PDX models have been used to identify metabolic as well as imaging biomarkers (42, 43).

Equally important is the discovery of resistance biomarkers that may help to design combination clinical trials. In colorectal cancer, it has been shown that tumors resistant to EGFR inhibition harbor amplifications of other genes such

as *HER2* and *MET* (28, 44). Preclinical combination studies with agents targeting these genes showed promising preclinical efficacy resulting in clinical translation. Likewise, in SCCHN, activating mutations in the *PIK3CA* gene confer resistance to EGFR inhibitors that can be modulated by agents that inhibit the PI3K pathway (25). PDX models are also versatile tools for simulating resistance when exposed to treatment strategies used in the clinical setting. This has been shown for example in ovarian cancer, in which prolonged exposure to cisplatin results in the induction of resistance to this agent in a platinum-sensitive model, similar to what is observed in the clinical setting. This model has been used to explore new agents, with a goal to select drugs to be tested in platinum-resistant patients such as the DNA minor groove binder lurbinectedin (18). Interestingly, cisplatin-sensitive and cisplatin-resistant ovarian orthoxenografts recapitulate characteristic features of primary human tumor response, such as the histopathologic tumor regression criteria associated with patient treatment response (36). Resistance to targeted drugs, such as vemurafenib, has been induced in melanoma PDX models. Not only was a mechanism of resistance was identified, but also a novel drug administration strategy applicable to the clinic was proposed to overcome resistance (45). Until now, no published work compared PDX models established from primary and recurrent tumor samples from the same patient.

Preclinical testing in PDX models can also facilitate optimization of clinical trial design. This is perhaps best illustrated in studies with cancer stem cell (CSC) therapeutics such as inhibitors of the Sonic Hedgehog, Nodal/Activin, TGF β , and Notch pathways (46–49). In PDX studies, these agents failed to induce synergistic tumor regression responses when combined with chemotherapy but resulted in tumor growth delay and, importantly, in a decrease in tumor initiation and relapse. In addition, in reimplantation studies, it was shown that administration of an agent directed at CSCs prevented reengraftment of treated tumors when excised and reinjected in host mice (49). The use of PDX models in this context is crucial to assess and understand the effect of pharmacologic compounds on CSCs. These findings may have further implications for clinical trial design, as it would suggest that treatment of minimal residual disease (such as during the postoperative period or after debulking chemotherapy) and using a time-to-event endpoint may be an appropriate setting in which to apply this approach.

On the basis of these data, PDX models may play an important role in drug–response studies to help select populations of patients most likely to be sensitive to a new agent, as well as to prioritize the development of new biomarkers. Figure 1 depicts a proposed path for the integration of PDX models in new drug development. For agents that are selected for clinical studies, we propose to perform PDX testing in parallel to phase I safety and pharmacologic studies. PDX preclinical testing should be done in tumor types of interest selected by prior preclinical data both with regard to disease type but also in molecularly defined groups as in basket-type trials. Indeed, one of the advantages of the existing PDX model collections is that they have been extensively characterized at the histologic, molecular, and genomic level. On the basis of the type of agent, studies can be adapted to test single agents or clinically meaningful combinations, using appropriate endpoints such as response rate (short-response assay) or tumor growth delay (long-term response). Agents showing activity in initial screens can be further studied in a larger group of models using statistical methodologies similar to two-stage clinical trial design. Once again, the availability of a larger collection of models through the collaboration of academic and nonprofit organizations would enable these larger screens. Biologic and genetic comparisons between sensitive and resistant models can be explored for the prioritization of biomarkers for inclusion in clinical studies.

Co-Clinical Trials

Once a drug enters clinical trials, there are limited opportunities to, on a real-time basis, analyze and integrate information that may be useful for the development of that agent (50). Even in studies that select patients based on molecular abnormalities and that incorporate tumor tissue, normal tissue, and imaging-based pharmacodynamic endpoints, there are few options for real-time integration and exploitation of the observed information in the trial. This is in part due to the intrinsic nature of clinical trials in which patients are treated with one drug or regimen at a time and followed under very specific criteria, but also due to the lack of sufficient and easily accessible biological materials for more in-depth studies of clinical observations. Thus, patients may develop extreme responses or rapid resistance, but it is in general difficult to study the underlying mechanisms in detail.

To solve some of these issues, the concept of co-clinical trials has been proposed. In their original format, these studies refer to the use of GEMMs of cancer to determine patient selection strategies as well as to discover mechanisms of resistance to treatment approaches (51, 52). PDX models have been used in this context in parallel studies in rodent models and patients, and have indeed been useful in identifying potential biomarkers (39, 53). Moreover, PDX models may also be used in another application of the co-clinical trial concept, as depicted in Fig. 2. In this approach, a personalized PDX model, a so-called “Avatar” model, is developed from a patient enrolled in a clinical trial and treated with the same experimental agents to emulate clinical response. This strategy permits the assessment of drug response simultaneously in the patient and mouse model, providing an interesting platform to investigate biomarkers of susceptibility and resistance, as well as interrogation of novel combination strategies to overcome emergent resistance pathways.

Personalized Medicine

The field of oncology is rapidly evolving from an “all comers” approach to cancer therapy to an era in which patients' tumors are profiled in greater detail to select the most appropriate treatment (54). Colorectal cancer, NSCLC, and human breast cancer tumors, to name a few, are now routinely profiled to aid in the treatment decision-making process (55). Furthermore, cell free circulating tumor DNA is now also analyzed to direct patients to appropriate clinical trials with molecularly targeted agents (56). Although this tailored strategy represents a significant advancement in translational cancer research, further advancements are required. One such outstanding advancement requires consideration of patients for whom, despite extensive testing, no biomarkers of drug efficacy are detected. These patients cannot have their treatment personalized. The opposite situation is also true: as cancer profiling evolves and becomes more comprehensive, multiple potential targets are identified in some patients, confounding the selection of the most appropriate one.

Avatar mouse models have been used to personalize cancer treatment (57). Interest in using these models emerges from studies such as those listed in Table 3 that have demonstrated a remarkable correlation between drug response in PDX models and clinical response. In NSCLC, for example, PDX models have been used to test the efficacy of three of the most commonly used first-line chemotherapy regimens in this setting. The results of this study show that approximately two thirds of the patients with NSCLC are sensitive to first-line chemotherapy, whereas one third are resistant. Interestingly, patients are not sensitive to all regimens equally and some patients are sensitive to one but resistant to another, suggesting that there is potential to personalize regimen selection (20). In another study, investigators used Avatar models from patients with advanced cancer to screen a large battery of anticancer agents and select the most effective agent to treat the donor patient. The results of this trial show that when all factors involved are correctly aligned, the response in Avatars and patients is highly correlated. However, in most patients, the approach is not feasible for reasons such as failure of the tumor to engraft, lack of effective agents, and length of time required for a complete study (33, 35). Thus, strategies to optimize these issues, as discussed below, are needed.

It is likely that the contribution of PDX models to personalized cancer treatment will increase by their integration in more global personalized medicine approaches like the one represented in Fig. 3, rather than as a stand-alone platform. The significant revolution in cancer genetics is permitting, for the first time, the gathering of enormous amounts of genomic information, including the assessment of a complete cancer genome, to aid in clinical decision-making (55, 58). In many oncology clinics, it is now becoming common practice to analyze a set of 50 to 100 relevant cancer genes for hundreds of mutations. From this approach, numerous potential targets have emerged for individual patients that may potentially be linked to clinical response. In addition to bioinformatics and *in silico* prediction data from cancer cell line data, personalized PDX models may now be useful in this setting, as they facilitate testing of candidate regimens in the patient's own tumor to select for the most efficacious treatment approach (3, 59). Furthermore, the integration of observed responses in mice with the tumor genetic information would eventually lead to the discovery of new biomarkers of drug efficacy. For patients whose tumors do not take in mice or those who require a long time to be established and characterized, an alternative to the Avatar strategy could be to orient treatment choice based on drug response of a similar PDX. Biopsies of primary tumors or metastases would be molecularly characterized and compared with available

PDX collections from the same pathology, for which responses to chemotherapies and targeted agents have been previously determined (Supplementary Fig. S1).

Limitations of PDX Models

Although the incorporation of PDX models in cancer research brings some improvements as detailed above, it is clear that they still have important limitations that need to be addressed to improve their use in translational cancer research. Some of these limitations are technical in nature and include several issues, such as (i) consideration of the most appropriate tissue from which to generate a PDX model and the processing of this tissue. Most of the published studies have relied on surgical specimens that naturally provide large quantities of tissues. Although this approach is useful to generate PDX collections, smaller samples, such as tumor biopsies or fine-needle aspirations, are better suited for personalized medicine applications. (ii) It is important to define the best strategy of engraftment in mice (subcutaneous vs. orthotopic implantation) for different tumor types. (iii) Delay between engraftment time in mice and treatment schedules for patients is also a limiting factor for real-time personalized medicine applications. It normally takes 4 to 8 months to develop a PDX model ready for a preclinical study, a time frame that many patients do not have. (iv) Another problem is engraftment failure that is still high for some tumor types with particular phenotypes, such as hormone receptor-positive human breast cancer. For personalized medicine strategies, it is mandatory to improve tumor take rates to an acceptable 60% to 70%, this being one of the main aspects requiring improvement. This is not only a problem in personalized medicine, as most patients do not have a linked PDX model, but also in drug-screening studies, as current PDX collections are skewed toward certain cancer subtypes and do not broadly represent the disease heterogeneity.

One key aspect in PDX research is the need to use immunodeficient host strains for tumor engraftment and propagation. These mice lack functional elements of the immune system (Supplementary Table S1) to avoid rejection of foreign tissues and permit engraftment of the tumor. For this reason, PDX models are of limited use in screening immune-mediating agents, such as vaccines and immune modulators (e.g., anti-PD1), or agents that function by activating immune elements, such as anti-CD40 antibodies.

Another critical aspect is the substitution of human tumor by murine stroma throughout tumor growth in mice. In different studies in which this aspect has been addressed, it has been consistently shown that the human cancer stroma included in the implanted tumor pieces is rapidly replaced by murine stroma, so that after three to five passages when the models can be used for drug testing, stroma is in essence murine. This includes the extracellular matrix, cancer-associated fibroblasts, blood vessels, and inflammatory and immune-mediating cells such as leukocytes and macrophages. This new murine stroma probably results in changes in paracrine regulation of the tumor as well as in physical properties such as interstitial pressure, that may limit the study of agents directed against this tumor compartment (50, 60).

An important use of preclinical models in cancer research is for drug screening. Traditionally, this has been done using established cell lines that, as mentioned above, have very poor predictive value and are overly permissive. Using PDX models for this application would be ideal, although at the present time, cost and resources required make this approach unfeasible. As an alternative, some groups are using short-term single-cell suspensions and short-term culture in organoid bioreactors.

The process of generating a PDX model clearly results in the selection of tumors that engraft and propagate in mice. This has been shown across multiple studies with the general impression that more aggressive tumors have a higher take rate. In human breast cancer, for example, hormone receptor-negative tumors have a higher take rate than hormone-sensitive tumors and are overrepresented in the existing PDX collections (16, 30,34). Patients with human breast cancer, RCC, PDAC, and uveal melanoma whose tumors successfully engraft show the worst prognosis, indicating that there is a selection toward more aggressive higher metastatic tumors (14, 15, 22, 30, 33, 61). In addition, although this is still poorly understood, it is possible that tumors that engraft do so by propagation of selected clones that divide actively to form a new tumor in the host mice that is not necessarily identical to the parental tumor. Thus, although

in general there are close similarities in global genetic surveys such as unsupervised clustering analyses between a PDX model and the original patient tumor, there are still likely changes in more specific genes and drug targets. In that sense, some studies have shown that there are discrepancies in the expression of selected drug targets and subtle variations in the expression of gene signatures reflecting stromal, immune infiltrate, or angiogenesis components. Indeed, several studies have reported that the gene expression profile and genetic characteristics of PDX models are reminiscent of the cancer metastasis and relapse environment (15, 24, 33).

Future Directions

Over the last few years, there has been a growing interest in developing PDX collections and using them for different cancer research applications (11, 12). Although there has been important progress in the field, there are several crucial areas that will benefit from additional research. These include such diverse issues as implantation procedures, consideration of mouse host strain, post-engraftment manipulations, robust application of translational imaging modalities in the assessment of PDX models toward the elucidation of imaging response biomarkers, and nomenclature and harmonization in study design and reporting. Furthermore, because of significant expansion in the field, organized and collaborative efforts will also be needed to optimize the use of existing collections and the generation of new ones.

As mentioned above, the process of generating PDX models is, in general, well established and implemented in a consistent fashion by most research groups (10, 13). However, each research group has developed its own approach and few comparative methodologic studies are available. Issues such as the minimum sample size needed, best preservation media, the need to add other components, such as Matrigel or mesenchymal cells, site of implantation (subcutaneous, orthotopic, or renal cell capsule), and time spent on processing the specimen for better results are currently unknown. Of major importance, particularly for personalized medicine applications, is the development of methods to increase engraftment rates and to generate models from difficult-to-engraft cancer types such as prostate cancer or hormone-dependent human breast cancer. Of great interest in this sense are newer three-dimensional models of glioblastoma, colorectal cancer, and human breast cancer, for example. These tissue-originated spheroids are generated by digesting and growing primary tumor cells under controlled culture conditions (62). Spheroids can survive for several days under *in vitro* conditions, can be subjected to *ex vivo* manipulation, and can generate full tumors, of even well-differentiated histology, when implanted in mice (63). Likewise, flow cytometry strategies to purify tumor-initiating cells before implantation in mice can improve engraftment rates (64).

Once a PDX model has been developed, there is also interest in generating cell lines to facilitate high-throughput drug-screening and functional studies (65). However, as discussed above, any *ex vivo* manipulation may preempt significant modifications in fundamental biologic properties of the tumor, thus compromising the translational value of the models (27).

It is now well established that cancer is genetically heterogeneous in an inter- and intra-individual manner and that there is a genetic evolution in cancer as the tumor progresses (66–68). Thus, a PDX model generated from one individual lesion at a single time point is indeed a snapshot view of a tremendously dynamic process and may not be representative of the full diversity of the disease. Furthermore, the process of PDX generation, as discussed in detail above, selects for more aggressive tumors and likely for more aggressive clones, with metastatic features, within the tumor. At present, there are no solutions to this issue. However, recent studies attempting to generate PDX models from circulating tumor cells have shown promising early results (69). One approach to at least partially overcome this problem is the generation of models from rapid autopsy programs that permit sampling of multiple lesions from the same cancer (70). In addition to their role in studies of cancer evolution, these models are also a better representation of end-stage disease, which is where new drugs are ultimately tested. Furthermore, it is to be expected that the more rigorous grafting of tumors before, during, and after treatments, as it is being performed nowadays, will also result in novel PDX models from paired clinically drug-sensitive and drug-resistant tumors.

One key aspect in PDX research is the host mouse model used. With the premise that immunodeficient hosts are required to allow engraftment, investigators have used different mouse strains to generate PDX collections. These strains differ with regard to their immune system deficiencies and provide different permissive environments (Supplementary Table S1). The prevailing notion that a more severely immunodeficient mouse is a better host has not been properly assessed. Although this question may not be relevant for small-scale experiments, large preclinical studies, which use hundreds of mice, would benefit from the use of cheaper and less delicate strains. Of major interest, however, is the development of mouse models with reconstituted immune systems from the individual donor, or models able to replicate human, rather than murine, stroma (71). A “personalized immune” mouse, with a robust immune reconstitution with hematopoietic stem cells aspirated from the bone marrow of an individual patient with cancer, may provide a new model to observe the role of the autologous immune response in the PDX setting of the same patient with cancer. These models would permit the testing of agents directed against the immune system or the stromal component.

Another critical requirement is the ability to noninvasively and longitudinally monitor PDX tumor growth kinetics and response to therapies. Small animal imaging techniques, such as computed tomography, magnetic resonance imaging, and positron-emission tomography, allow for detailed appraisal of tumor anatomy, vascularization, and metabolic activity (72). Nevertheless, these approaches are limited with respect to high-throughput implementation and require costly equipment and infrastructure and a high level of technical expertise. Conversely, bioluminescence imaging (BLI) requires ectopic transduction of a light-emitting enzyme (usually luciferase) in tumor cells, but represents a cost-effective and relatively high-throughput and facile preclinical imaging modality (73). Recent studies have reported efficient expression of exogenous proteins, including luciferase, by infecting patient-derived tumor-cell suspensions and spheroid cultures with lentiviral particles (74). Although these advancements attest to the feasibility of genetic modification of PDX tumor preparations for imaging purposes, their utility in the routine implementation of BLI to follow PDX tumors *in vivo* remains to be seen.

Efforts to harmonize and standardize study design and data analysis are also needed. For PDX preclinical studies to be fully integrated in clinical development pipelines, there first needs to be a consensus in the design of preclinical studies. This includes areas such as the number of models representing the tumor heterogeneity of the majority of tumor types, and the number of mice per model required for robust statistical interrogation, as per a clinical trial. Another important question is the homogeneity of the batch of mice in which a drug will be assayed, important when a large number of mice are needed. A key question is the efficacy endpoint selected and the degree of efficacy required for a positive result. For example, when testing conventional cytotoxic agents, tumor regression may be the preferred endpoint, whereas if testing agents against the CSC compartment, endpoints such as growth delay and latency to growth after retransplantation may be favored. Regardless of the selected endpoint, a consensus is needed in reference to the level of activity considered sufficient to advance an agent to clinical development.

As the number of groups, both in industry and in academia, working on developing PDX collections increases, efforts to develop collaborative networks are ongoing. These networks will likely house thousands of models with well-annotated biologic, clinical, and drug-response data. With proper confidentiality and data protection systems, this information can be shared to permit the rapid assessment of model availability, which will be particularly important for rare molecularly defined tumor types. Furthermore, these networks will allow the conducting of multicenter preclinical trials as done for patients under a single protocol with rapid accrual and data generation.

In that sense, within Europe, a consortium of centers having interest and significant expertise in PDX models has now emerged: EurOPDX is an initiative of translational and clinical researchers across Europe having the common goal to create a network of clinically relevant and annotated models of human cancer, and in particular PDX models. The primary goal of our initiative is to share PDX models in diverse cancer pathologies, to constitute a unique collection reproducing the heterogeneity of human cancer. Supplementary Table S2 provides a summary of the models and the level of characterization of those models currently available across the EurOPDX Consortium.

A shared database with harmonized annotation of models will be established and integrative systems-based analyses developed to elucidate novel therapeutic strategies and to uncover predictive biomarkers for personalized cancer

treatment. Annotation of the models will include anatomopathologic data, clinicopathologic data from the patients the PDX models were derived from, deep molecular profiling in particular with gene expression, CNAs, and proteomics platforms, as well as pharmacogenomic data corresponding to current anticancer therapies. Additional technologies such as imaging are increasingly being used, and the ideal database will also include such data as well as scanned images of pathology slides (75). In this way, the consortium will be able to quickly include any newly developed multimodal prognostic and predictive tool in the analysis pipeline. Making the data available for the analysis is not a trivial task as it implies standardization of platforms used for molecular characterization, data acquisition, data curation, normalization, and quality control. Moreover, and as discussed above, harmonization and standardization of working practices for the implementation and use of PDX models and, in particular, for the performance of more reproducible and predictive multicenter preclinical trials will be a key objective of the network.

Hypotheses will then be validated in proof-of-concept collaborative multicenter PDX trials within molecularly defined tumor subsets and on a population scale, as a prelude for prospective clinical trials in humans. The consortium will be in absolute compliance with European rules for the use of experimental animals. A coordinated and rational design of the experiments, troubleshooting, and sharing of positive and negative results across the various centers will enable a reduction in the overall number of experimental animals used and optimize the use of each precious patient sample, avoiding unnecessary replicas of experiments, while maximizing the statistical significance and robustness of the data.

Finally, the performance of research programs among this academic consortium will allow us to address the current limitations of the PDX models described above and advance their use as clinically relevant cancer models.

Through the building of this network and its collaboration with pharmaceutical and biotech companies, the EurOPDX initiative will accelerate the emergence of novel therapeutic strategies with a real impact on quality of life and overall survival of patients with cancer through more predictive preclinical or “co-clinical” data, ultimately reducing attrition rates in oncology clinical trials in Europe.

Conclusions

Over the last decade, there has been an interest in developing and characterizing collections of PDX models from different cancer types, which are now available at academic and nonprofit organizations. These models are becoming an integral part of the drug development arena, including drug screening and biomarker development. In addition, PDX models bear the promise of assisting clinical trial designs as well as being integrated into personalized medicine strategies. It is envisioned that PDX models will eventually play a broader role in the drug development process and become a must-have element in that process. At present, however, there are still some critical issues that must be addressed to make this platform more useful and informative. This includes increasing the take rate and time to model generation, recapitulation of the human stroma and immune-related elements, as well as strategies to develop models more representative of different cancer entities, tumor heterogeneity, and chemorefractory patients. Finally, initiatives to harmonize nomenclature, study designs, and procedures are needed. We propose that the new European EurOPDX initiative, which represents a PDX collaborative consortium, will offer a unique opportunity to address translational challenges in oncology research.

Disclosure of Potential Conflicts of Interest

M. Hidalgo is a founder and shareholder of Champions Oncology, Inc. No potential conflicts of interest were disclosed by the other authors.

Grant Support

A.T. Byrne is supported by the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT GrantCCRC13GAL and further receives funding from the European Union's Seventh Framework Programme for

research, technological development and demonstration under grant agreements no. 278981 "AngioPredict" and no. 306021 "Apodecide."

Acknowledgments

The authors thank all the additional scientific collaborators and institutions contributing to the EurOPDX Consortium project: Virginie Dangles-Marie, Didier Decaudin, Elisabetta Marangoni, Fariba Nemati (Institut Curie, Paris, France); Pedro P. Lopez-Casas (Centro Nacional de Investigaciones Oncológicas, Madrid, Spain); Andrea Bertotti, Enzo Medico (IRCC, Institute for Cancer Research and Treatment—Department of Oncology, University of Torino, Candiolo, Torino, Italy); Lieve Coenegrachts, Els Hermans, Diether Lambrechts, Jean-Christophe Marine, Sabine Tejpar (Katholieke Universiteit Leuven, Leuven, Belgium); Jean-Pascal Machiels (Université Catholique de Louvain, Bruxelles, Belgium); Joaquín Arribas, Yasir Ibrahim, Héctor Palmer, Alejandro Piris, Violeta Serra, Laura Soucek (Vall d'Hebron Institut of Oncology, Barcelona, Spain); Gabriel Capella, Oriol Casanovas, Eva Gonzalez-Suarez, Conxi Lazaro, David G. Mollevi, Puri Muñoz, Miguel Angel Pujana, Francesc Viñals (Catalan Institute of Oncology – Bellvitge Biomedical Research Institute, Barcelona, Spain); Petra Ter Brugge, Jelle Wesseling, Daniel Peeper, Kristel Kemper (The Netherlands Cancer Institute, Amsterdam, the Netherlands); Ate van der Zee, Bea Wisman (University Medical Center Groningen, Groningen, the Netherlands); Alejandra Bruna (Cambridge Cancer Center, Cambridge, United Kingdom); Denis Alferez (Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom); Caroline Dive, Richard Marais, Christopher Morrow (Cancer Research UK Manchester Institute, Manchester, United Kingdom); David Chang, Jennifer P. Morton, Owen Sansom (WWCRC/Beatson Institute, Glasgow, United Kingdom); Vlad Popovici (Masaryk University, Brno, Czech Republic); Anne-Lise Børresen-Dale, Kjersti Flatmark, Olav Engebråten (Oslo University Hospital, Oslo, Norway); and Emilie Vinolo (seeding science EURL, Paris, France) as the project manager for the Consortium. Additional acknowledgments go to all other collaborators of the above-mentioned institutions involved in the development of the PDX models and associated research, and all funding agencies, as well as Marina Pajic (Garvan Institute of Medical Research, Sydney, Australia) and the Australian Pancreatic Cancer Genome Initiative (www.pancreaticcancer.net.au).

References

1. Boyd M. The NCI *in vitro* antitumor drug discovery screen: concept, implementation, and operation, 1985–1995. In: Teicher B, editor. Anticancer drug development guide: preclinical screening, clinical trials and approval. Totowa, NJ: Humana Press; 1997.
2. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening *in vivo*: results of tumor panel screening, 1976–1982, and future directions. *Adv Pharmacol Chemother* 1984;20:1–20.
3. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. *Cancer Res* 2013;73:4372–82.
4. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical *in vitro* and *in vivo* models and early clinical trials. *Br J Cancer* 2001;84:1424–31.
5. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proc Natl Acad Sci U S A* 2011;108:18708–13.
6. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. *Biochem Biophys Res Commun* 2005;333:216–22.
7. Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. *Recent Results Cancer Res* 1985;97:77–86.

8. Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. *Cancer Res* 1982;42:535–9.
9. Berger DP, Fiebig HH, Winterhalter BR, Wallbrecher E, Henss H. Preclinical phase II study of ifosfamide in human tumour xenografts *in vivo*. *Cancer Chemother Pharmacol* 1990;26(Suppl):S7–11.
10. Calles A, Rubio-Viqueira B, Hidalgo M. Primary human non–small cell lung and pancreatic tumorgraft models—utility and applications in drug discovery and tumor biology. *Curr Protoc Pharmacol* 2013;Chapter 14:Unit 14 26.
11. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. *Cancer Res* 2013;73:5315–9.
12. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol* 2012;9:338–50.
13. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. *Nat Protoc* 2009;4:1670–80.
14. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. *Clin Cancer Res* 2010;16:2352–62.
15. Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. *Sci Transl Med* 2012;4:137ra75.
16. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. *Cancer Res* 2013;73:4885–97.
17. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 2007;1:555–67.
18. Vidal A, Munoz C, Guillen MJ, Moreto J, Puertas S, Martinez-Iniesta M, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. *Clin Cancer Res* 2012;18:5399–411.
19. Wang X, Fu X, Hoffman RM. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. *Int J Cancer* 1992;51:992–5.
20. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, et al. Patient-derived first generation xenografts of non–small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. *Clin Cancer Res* 2010;16:1442–51.
21. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers. *Clin Cancer Res* 2008;14:6456–68.
22. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Rep* 2013;4:1116–30.
23. Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O. Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations. *Cancer* 2012;118:558–70.
24. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. *Nature* 2010;464:999–1005.

25. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. *Mol Oncol* 2013;7:776–90.
26. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An *in vivo* platform for translational drug development in pancreatic cancer. *Clin Cancer Res* 2006;12:4652–61.
27. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture *in vitro*. *Cancer Res* 2009;69:3364–73.
28. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov* 2011;1:508–23.
29. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. *Clin Cancer Res* 2012;18:5314–28.
30. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. *Nat Med* 2011;17:1514–20.
31. Reyat F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular profiling of patient-derived breast cancer xenografts. *Breast Cancer Res* 2012;14:R11.
32. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Borresen-Dale AL, et al. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. *BMC Cancer* 2010;10:433.
33. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. *Clin Cancer Res* 2011;17:5793–800.
34. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. *Clin Cancer Res* 2007;13:3989–98.
35. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Ther* 2011;10:1311–6.
36. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov* 2004;3:711–5.
37. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. *Clin Cancer Res* 2012;18:2515–25.
38. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691–703.
39. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. *Br J Cancer* 2010;103:649–55.
40. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. *Clin Cancer Res* 2009;15:4138–46.

41. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. *Clin Cancer Res* 2006;12:2492–7.
42. Moestue S, Sitter B, Bathen TF, Tessem MB, Gribbestad IS. HR MAS MR spectroscopy in metabolic characterization of cancer. *Curr Top Med Chem* 2011;11:2–26.
43. Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Maelandsmo GM, et al. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. *J Magn Reson Imaging* 2013;38:1043–53.
44. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov* 2013;3:658–73.
45. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. *Nature* 2013;494:251–5.
46. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. *Cancer Cell* 2010;18:655–68.
47. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell Stem Cell* 2011;9:433–46.
48. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. *Gastroenterology* 2009;137:1102–13.
49. Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, et al. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. *Clin Cancer Res* 2012;18:5374–86.
50. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature* 2013;501:346–54.
51. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature* 2012;483:613–7.
52. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. The APL paradigm and the “co-clinical trial” project. *Cancer Discov* 2011;1:108–16.
53. Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. *Mol Cancer Ther* 2006;5:3240–7.
54. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. *Cell* 2012;148:409–20.
55. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. *J Clin Oncol* 2013;31:1806–14.
56. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012;486:537–40.
57. Garber K. Personal mouse colonies give hope for pancreatic cancer patients. *J Natl Cancer Inst* 2007;99:105–7.
58. Valencia A, Hidalgo M. Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. *Genome Med* 2012;4:61.

59. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012;483:603–7.
60. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. *J Pathol* 2003;200:429–47.
61. Kleine W. Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice. *Gynecol Oncol* 1986;25:65–72.
62. Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M, et al. Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. *Proc Natl Acad Sci U S A* 2011;108:6235–40.
63. Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelieres FP, et al. Newly characterised *ex vivo* colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. *Br J Cancer* 2009;101:473–82.
64. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. *Nat Biotechnol* 2011;29:1120–7.
65. Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, et al. Personalized chemotherapy profiling using cancer cell lines from selectable mice. *Clin Cancer Res* 2013;19:1139–46.
66. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* 2012;366:883–92.
67. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* 2012;486:395–9.
68. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature* 2010;467:1114–7.
69. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. *Nat Biotechnol* 2013;31:539–44.
70. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boor Witzel S, Seigel A, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. *Cancer Biol Ther* 2005;4:548–54.
71. Kalscheuer H, Danzl N, Onoe T, Faust T, Winchester R, Golland R, et al. A model for personalized *in vivo* analysis of human immune responsiveness. *Sci Transl Med* 2012;4:125ra30.
72. van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. *Drug Discov Today* 2010;15:102–14.
73. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imaging: a critical tool in pre-clinical oncology research. *J Pathol* 2010;220:317–27.
74. Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. *Cell Stem Cell* 2008;2:90–102.
75. Yuan Y, Failmezger H, Rueda OM, Ali HR, Graf S, Chin SF, et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. *Sci Transl Med* 2012;4:157ra43.
76. Aytes A, Mollevi DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A, et al. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. *Mol Carcinog* 2012;51:746–53.

77. Reyes G, Villanueva A, Garcia C, Sancho FJ, Piulats J, Lluís F, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. *Cancer Res* 1996;56:5713–9.

78. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. *Clin Cancer Res* 2013;19:855–64.

Table 1.

Key methodologic aspects of selected PDX collections

Reference	Tumor type	Available models	Origin	Procurement	Processing	Mice strain	Implantation site	Engraftment rate
(28)	CRC	130	Metastasis	Surgery	Fresh tumor pieces in Matrigel	NOD/SCID	s.c.	87%
(29)	CRC	54	Primary (35) Metastasis (19)	Surgery	Fresh tumor pieces	Nude	s.c.	64%
(78)	CRC	41	Primary	Surgery	Fresh tumor pieces	Nude	Orthotopic	89.1%
(34)	HBC	25	Primary	Surgery	Fresh tumor pieces	Nude	s.c.	13%
(30)	HBC	12	Primary (4) Metastasis (8)	Surgery/fluid drainage	Fresh tumor pieces in Matrigel	NOD/SCID with estrogen supplementation for ER ⁺ tumors	Mammary fat pad	27%
(18)	HBC	24	Primary	Biopsies/surgery/fluid drainage	Fresh tumor pieces	SCID/Beige and NSG w/wo estrogen and immortalized human fibro-blasts	Mammary fat pad	3%–21%
(21)	NSCLC	25	Primary	Surgery	Fresh tumor pieces	NOD/SCID	s.c.	25%
(20, 22)	NSCLC	32	Primary	Surgery	Fresh tumor pieces	NOD/SCID	Renal capsule	90%
(33)	PDAC	42	Primary	Surgery	Fresh tumor pieces in Matrigel	Nude	s.c.	61%
(28)	PDAC	14	Primary	Surgery	Fresh tumor pieces in Matrigel	Nude	s.c.	NR
(77)	PDAC	16	Primary (11) Metastasis (5)	Surgery	Fresh tumor pieces	Nude	Orthotopic	62%
(78)	SCCHN	22	Primary	Biopsy/surgery	Fresh tumor pieces in Matrigel	NSG	s.c.	85%
(25)	SCCHN/SCC	21	Primary	Surgery	Fresh tumor pieces in Matrigel	Nude	s.c.	54%
							FOM/FOT	
(14)	Uveal Melanoma	25	Primary (73) Metastasis (17)	Surgery	Fresh tumor pieces	NOD/SCID	s.c.	28%

NOTE: This table provides a summary of the methodologic approaches used to generate the most comprehensive PDX collections currently available.

Abbreviations: CRC, colorectal cancer; FOM, floor of the mouth; FOT, floor of the tongue; HBC, human breast cancer; NR, not reported; PDAC, pancreatic ductal adenocarcinoma; RCC, renal cell cancer; s.c., subcutaneous implantation; SCC, squamous cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck.

Table 2.

Fidelity and stability of PDX models

Reference	Tumor type	Original tumor-first passage	Subsequent passages
(²⁸)	CRC	Conserved histopathology characteristics between donor and PDX models.	Stable CNA across passages.
		Similarities in CNA between donor and PDX models.	
		Consistent <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , and <i>PI3K</i> mutation status.	
(²⁹)	CRC	Unsupervised clustering analysis using aCGH and GE shows that the donor tumors and PDX clustered together.	Stable aCGH and GE profile across passages.
		203 differentially expressed annotated genes correspond to stroma-related genes and pathways.	
(³¹ , ³⁴)	HBC	Conserved IHC expression of ER, PR, and HER2.	Stable CNA and GE profile across passages.
		Analysis of CNA showed 14/18 paired tumors–PDX shared more than 56% CNA.	Variations in stromal related genes.
		16/18 paired tumors–PDX clustered together in unsupervised hierarchical analysis.	
		PDX showed losses in 176 and gains in 202 chromosome regions compared with primary tumors.	
		Stable GE profile with less than 5% variations.	
(³⁰)	HBC	Conserved histopathology characteristics between donor and PDX models.	Stable IHC profile over time.
		Conserved IHC expression for CK, E-cadherin, β -catenin, vimentin, ER, PR, and HER2.	
		Unsupervised clustering analysis using GE shows that donor tumors and PDX clustered together.	
		Maintenance in the pattern of CNA.	
		Intrinsic breast cancer subtypes concordant between the donor tumors and PDX.	
(¹⁸)	HBC	Conserved histopathology characteristics between donor and PDX models.	Stable histopathologic and IHC expression.
		Conserved IHC expression for CK, p53, Ki67, ER, PR, HER2, and EGFR.	Stable GE, RPPA, and SNP across passages.
		Intrinsic breast cancer subtypes represented in PDX models.	
(²¹)	NSCLC	Conserved histopathologic characteristics between donor and PDX models.	
		Conserved IHC expression of Ki67 and EpCAM.	
		Unsupervised clustering analysis using GE shows the donor tumors and PDX clustered together with correlation coefficient ranging from 0.78 to 0.94.	
		134 differentially expressed genes correspond to cell adhesion and immune response genes and pathways.	
(²⁶ , ³³)	PDAC	Concordance in mutations in <i>KRAS</i> and <i>DPC4</i> .	Concordance in gemcitabine response between F3 and F6.
		Conserved GE profile ($R^2 = 0.69$).	Enrichment in angiogenesis gene signature in F5.
(²⁵)	SCC/SCCHN	Conserved histopathologic characteristics between donor and PDX models.	High correlation ($R^2 \sim 0.94$) in GE from F2–F4.
		High correlation ($R^2 = 0.91$) in EGFR expression.	Concordance in cetuximab response between F2 and F4.
		High correlation ($R^2 \sim 0.8$) in GE.	
		Variation in immune-related pathways.	
(¹⁵)	RCC	Conserved histopathologic characteristics.	Conserved histopathologic characteristics.
		Donor and PDX models cluster together in unsupervised hierarchical clustering analysis using GE.	Serial passages clustered together in unsupervised hierarchical clustering analysis.
		PDX retained CNA from the donor tumor.	Maintains CNA of the donor tumor.
		Similar mutation landscape in NGS studies.	

NOTE: This table summarizes the data from different studies in which PDX models have been compared with donor tumors using a variety of methods.

Abbreviations: aCGH, comparative genomic hybridization array; CRC, colorectal cancer; GE, gene expression; HBC, human breast cancer; IHC, immunohistochemistry; NGS, next-generation sequencing; PR, progesterone receptor; RCC, renal cell cancer; RPPA, reverse phase protein array; SNP, single-nucleotide polymorphism; SCC, squamous cell carcinoma.

Table 3.

Studies correlating PDX treatment results with clinical data

Tumor type (reference)	Definition activity	Standard agent	n	RR (%)	Clinical correlates
CRC	TR > 50%	Cetuximab	47	10	N/A
CRC <i>KRAS</i> WT ⁽²⁸⁾		Cetuximab	38	17	
CRC ⁽²⁹⁾	T/C < 10%	5-Fluorouracil	52	13	N/A
		Oxaliplatin	52	0	
		Irinotecan	49	38	
		Cetuximab	52	26	
HBC ⁽³⁴⁾	Complete response	AC	17	76	Response to treatment in the PDX model was concordant with clinical data in 5/7 patients.
	TGI > 50% or T/C GD > 2-fold	Docetaxel	17	47	
		Trastuzumab	2	50	
		GnRH antagonist	1	100	
HBC ⁽¹⁶⁾	RR > 30%	Docetaxel	7	14	92% correlation between clinical responses and responses in PDX
		Doxorubicin	4	0	
		Trastuzumab-lapatinib	1	100	
NSCLC ⁽²⁰⁾	Statistically significant decrement in tumor area in treated vs. control tumors	Cisplatin-vinorelbine	32	28	PDX models from 6/7 patients with early recurrent disease were resistant to the clinically used regimen.
		Cisplatin-docetaxel	19	42	
		Cisplatin-gemcitabine	16	44	
NSCLC ⁽²¹⁾	T/C < 5%	Etoposide	25	4	N/A
		Carboplatin	25	12	
		Gemcitabine	25	12	
		Paclitaxel	25	16	
		Vinorelbine	11	0	
		Cetuximab	25	12	
		Erlotinib	25	1	
SCCHN ⁽²⁵⁾	T/C < 20%	Cetuximab	11	9%	N/A
RCC ⁽¹⁵⁾	Statistically significant differences in TGI	Sunitinib	8	Active	N/A
		Sirolimus		Active	
		Erlotinib		Inactive	
PDAC ⁽²⁶⁾	T/C < 20%	Gemcitabine	14	36	N/A
		Erlotinib		0	
		Temsirolimus		0	
PDAC ⁽³³⁾	TGI > 85%	Gemcitabine	23	17%	Response to gemcitabine in the PDX model predicted longer time to progression in patients.

NOTE: This table provides a summary of studies in which PDX models from different cancer types have been treated with agents used in the clinical care of these patients.

Abbreviations: AC, adriamycin-cyclophosphamide; CRC, colorectal cancer; GD, growth delay; GnRH, gonadotrophin-releasing hormone; HBC, human breast cancer; N/A, not available; RR, response rate; TGI, tumor growth inhibition; TR, tumor regression; T/C, treated divided by control; WT, wild-type.

Figure 1.

Proposed preclinical screening and biomarker study in PDX models. This figure graphically illustrates some of the key elements of a preclinical study in PDX models. These studies are likely to be more informative late in preclinical development or in parallel to phase I safety and pharmacology testing. Models can be selected on the basis of tumor types or on predefined molecular subtypes if that information is known and is of interest, or both. We propose a two-step approach. In step 1, a limited number of models can be tested with the agent at doses and schedules known to be effective and pharmacologically active in earlier preclinical studies. Study endpoints need to be carefully selected on the basis of the agent's mechanism of action. Data from step 1 can be used to proceed to step 2 and to redefine model selection based on the molecular understanding of responsive models. In step 2, a larger repertoire of models can be treated. At the conclusion of the study, a decision needs to be made to proceed to clinical development and prioritize biomarkers to be explored in the clinical phase. PD, pharmacodynamic.




Figure 2.

Co-clinical trial approach with PDX models. A new version of the co-clinical trial concept is presented in which a PDX model is developed from a patient enrolled and treated in a clinical trial with a novel agent. This approach permits models with validated clinical outcome data that can be used to interrogate mechanisms of response and resistance as well as strategies to increase response and overcome resistance, for example, combination strategies. D1, day 1.




Figure 3.

Personalized medicine strategy. Depicted in this figure is a strategy for individualizing medicine that integrates genomic analysis of a patient tumor with testing in Avatar mouse models. The genomic analysis of a patient tumor is likely to show tens of potentially therapeutically targetable mutations. Mining of genomic-drug response databases such as the Cancer Cell Line Encyclopedia (CCLE) or the NCI-60 as well as knowledge of these mutations is likely to result in several potential therapeutic regimens for a given patient. The Avatar model can be used to test and rank these potential treatments to be administered to the patient. A *post hoc* analysis of this information can be added to existing data to further feed into the existing databases.

